---
figid: PMC6689321__nihms-1533635-f0003
figlink: /pmc/articles/PMC6689321/figure/F3/
number: F3
caption: 'Extensive cross-talk exists between mitogenic signaling pathways and the
  CDK4/6 pathway in cancer cells. First, mitogenic signaling increases cyclin D1 levels
  to increase CDK4/6 activity via several mechanisms (red arrows): (a) PI3K pathway
  signaling reduces cyclin D1 turnover via GSK3β; (b) Ras pathway signaling promotes
  an ERK-dependent upregulation of transcription factors that drive cyclin D gene
  expression; (c) mTORC1 increases cyclin D protein translation; (d) CCND1 transcription
  is increased directly by activated ER (breast cancer) and AR (prostate cancer).
  In addition, these pathways also interact via their convergence on TSC2 and thus
  mTORCl: (a) ART, ERK, and p90RSK each directly phosphorylate TSC2 to activate mTORCl;
  (b) cyclin D-CDK4/6 also bind to and probably phosphorylate TSC2 to increase mTORCl
  activity (dashed line).Rationale for synergistic combination therapy regimens: CDK4/6
  inhibitors limit cell proliferation by reducing RB phosphorylation, but can also
  partially suppress TSC2 phosphorylation. Co-inhibiting the PI3K and/or Ras pathway
  not only reduces cyclin D1 levels (further enforcing RB activation), but also increases
  the suppression of TSC2 phosphorylation, maximizing mTORCl inhibition. Collectively,
  combined activation of RB and inhibition of mTORCl inhibition potently blocks progression
  of cells into S phase.'
pmcid: PMC6689321
papertitle: 'CDK4/6 inhibition in cancer: beyond cell cycle arrest.'
reftext: Shom Goel, et al. Trends Cell Biol. 2018 Nov;28(11):911-925.
pmc_ranked_result_index: '2440'
pathway_score: 0.9713936
filename: nihms-1533635-f0003.jpg
figtitle: Cross-talk between the CDK4/6 and mitogenic signaling pathways in cancer
year: '2018'
organisms:
- Homo sapiens
ndex: 733cda29-dec6-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6689321__nihms-1533635-f0003.html
  '@type': Dataset
  description: 'Extensive cross-talk exists between mitogenic signaling pathways and
    the CDK4/6 pathway in cancer cells. First, mitogenic signaling increases cyclin
    D1 levels to increase CDK4/6 activity via several mechanisms (red arrows): (a)
    PI3K pathway signaling reduces cyclin D1 turnover via GSK3β; (b) Ras pathway signaling
    promotes an ERK-dependent upregulation of transcription factors that drive cyclin
    D gene expression; (c) mTORC1 increases cyclin D protein translation; (d) CCND1
    transcription is increased directly by activated ER (breast cancer) and AR (prostate
    cancer). In addition, these pathways also interact via their convergence on TSC2
    and thus mTORCl: (a) ART, ERK, and p90RSK each directly phosphorylate TSC2 to
    activate mTORCl; (b) cyclin D-CDK4/6 also bind to and probably phosphorylate TSC2
    to increase mTORCl activity (dashed line).Rationale for synergistic combination
    therapy regimens: CDK4/6 inhibitors limit cell proliferation by reducing RB phosphorylation,
    but can also partially suppress TSC2 phosphorylation. Co-inhibiting the PI3K and/or
    Ras pathway not only reduces cyclin D1 levels (further enforcing RB activation),
    but also increases the suppression of TSC2 phosphorylation, maximizing mTORCl
    inhibition. Collectively, combined activation of RB and inhibition of mTORCl inhibition
    potently blocks progression of cells into S phase.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - RPS6KA4
  - MAP2K2
  - RPS6KA5
  - RPS6KA3
  - CDK6
  - BRAF
  - RPS6KA2
  - CCND3
  - MAPK1
  - CCND1
  - CCND2
  - GRB2
  - GSK3B
  - MAPK3
  - RAPGEF5
  - AR
  - CDK4
  - TSC2
  - AKT2
  - HRAS
  - KRAS
  - ARAF
  - RAF1
  - RPS6KA1
  - EIF4EBP1
  - NRAS
  - RPS6KA6
  - MAP2K1
  - RHEB
  - AKT3
  - AKT1
  - TSC1
  - SOS1
  - SOS2
  - OH
  - Steroid
  - Cancer
  - Cardiomyopathy
  - Noonan syndrome
genes:
- word: (P90RSK
  symbol: P90RSK
  source: bioentities_symbol
  hgnc_symbol: RPS6KA4
  entrez: '8986'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: (P90RSK
  symbol: P90RSK
  source: bioentities_symbol
  hgnc_symbol: RPS6KA5
  entrez: '9252'
- word: (P90RSK
  symbol: P90RSK
  source: bioentities_symbol
  hgnc_symbol: RPS6KA3
  entrez: '6197'
- word: CDK4/6
  symbol: CDK6
  source: hgnc_symbol
  hgnc_symbol: CDK6
  entrez: '1021'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: (P90RSK
  symbol: P90RSK
  source: bioentities_symbol
  hgnc_symbol: RPS6KA2
  entrez: '6196'
- word: (CyclinD
  symbol: Cyclin_D
  source: bioentities_symbol
  hgnc_symbol: CCND3
  entrez: '896'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: (CyclinD
  symbol: Cyclin_D
  source: bioentities_symbol
  hgnc_symbol: CCND1
  entrez: '595'
- word: (CyclinD
  symbol: Cyclin_D
  source: bioentities_symbol
  hgnc_symbol: CCND2
  entrez: '894'
- word: GRB2
  symbol: GRB2
  source: hgnc_symbol
  hgnc_symbol: GRB2
  entrez: '2885'
- word: GSK3B
  symbol: GSK3B
  source: hgnc_symbol
  hgnc_symbol: GSK3B
  entrez: '2932'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: GFR
  symbol: GFR
  source: hgnc_alias_symbol
  hgnc_symbol: RAPGEF5
  entrez: '9771'
- word: AR
  symbol: AR
  source: hgnc_symbol
  hgnc_symbol: AR
  entrez: '367'
- word: CDK4/6
  symbol: CDK4
  source: hgnc_symbol
  hgnc_symbol: CDK4
  entrez: '1019'
- word: TSC2
  symbol: TSC2
  source: hgnc_symbol
  hgnc_symbol: TSC2
  entrez: '7249'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: (P90RSK
  symbol: P90RSK
  source: bioentities_symbol
  hgnc_symbol: RPS6KA1
  entrez: '6195'
- word: 4EBP1
  symbol: 4E-BP1
  source: hgnc_alias_symbol
  hgnc_symbol: EIF4EBP1
  entrez: '1978'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: (P90RSK
  symbol: P90RSK
  source: bioentities_symbol
  hgnc_symbol: RPS6KA6
  entrez: '27330'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: RHEB
  symbol: RHEB
  source: hgnc_symbol
  hgnc_symbol: RHEB
  entrez: '6009'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: TSC1
  symbol: TSC1
  source: hgnc_symbol
  hgnc_symbol: TSC1
  entrez: '7248'
- word: sos
  symbol: SOS
  source: bioentities_symbol
  hgnc_symbol: SOS1
  entrez: '6654'
- word: sos
  symbol: SOS
  source: bioentities_symbol
  hgnc_symbol: SOS2
  entrez: '6655'
chemicals:
- word: OH
  source: MESH
  identifier: C031356
- word: Steroid
  source: MESH
  identifier: D013256
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
figid_alias: PMC6689321__F3
redirect_from: /figures/PMC6689321__F3
figtype: Figure
---
